Synonyms: Example 1B {WO2020014435A1] | LY-3484356 | LY3484356
Compound class:
Synthetic organic
Comment: Imlunestrant (LY3484356) is an oral, selective estrogen receptor degrader (SERD) [2-3]. It is an ER antagonist that inudces a sustained inhibition of ER-mediated gene transcription and tumour growth in ER+ve breast and endometrial cancers. The INN stipulates the (5R) configuration of the molecule.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bastian JA, Cohen JD, Rubio A, Sall DJ. (2020)
Selective estrogen receptor degraders. Patent number: WO2020014435A1. Assignee: Eli Lilly And Company. Priority date: 11/07/2019. Publication date: 16/01/2020. |
2. Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, Jeselsohn R, Jhaveri K, Curigliano G, Criscitiello C. (2023)
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?. Cancer Treat Rev, 117: 102569. [PMID:37146385] |
3. Hernando C, Ortega-Morillo B, Tapia M, Moragón S, Martínez MT, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B et al.. (2021)
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int J Mol Sci, 22 (15): 7812. [PMID:34360578] |